Clinical Trials Logo
  1. Home
  2. Post-Menopausal Osteoporosis
  3. NCT00551174

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment

Post-Menopausal Osteoporosis Clinical Trial

Official title:
Open Label, Parallel Group, Multicenter Study of Two Intravenous (IV) Ibandronate Dose Regimens (2 mg Every 2 Months and 3 mg Every 3 Months) in Women With Postmenopausal Osteoporosis Who Completed Trial BM16550

Clinical Trial Summary

This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550 (DIVA study; NCT00048074). Patients received Bonviva either 2 mg IV every 2 months, or 3 mg IV every 3 months. Patients also received daily supplementation with vitamin D and calcium. The anticipated time on study treatment was 2+ years, and the target sample size was 500+ individuals.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00551174
Study type Interventional
Source Hoffmann-La Roche
Contact
Status Completed
Phase Phase 4
Start date October 2004
Completion date November 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT01224717 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women Phase 1
Completed NCT00984893 - Intra-venous Zoledronic Acid Once Yearly N/A
Withdrawn NCT01826656 - Bone Healing in Healthy and Post-menopausal Osteoporotic Women N/A
Completed NCT00718861 - 3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs Phase 3
Completed NCT00081653 - A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva Phase 4
Completed NCT00503113 - A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease. Phase 4
Completed NCT00150969 - Vitamin K Supplementation in Post-Menopausal Osteopenia Phase 3
Completed NCT03432533 - A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis Phase 3
Completed NCT00545779 - BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy. Phase 4
Completed NCT00533650 - Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005) Phase 2
Active, not recruiting NCT01232647 - Vitamin K as Additive Treatment in Osteoporosis Phase 2/Phase 3
Completed NCT00666627 - Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects Phase 2